Monday, March 17, 2025 | 02:30 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Top headlines: Bharat Biotech's Covaxin off trial, IDBI Bank out of PCA

Saudi Aramco's $44-billion refinery project at Nanar in Ratnagiri has become a bone of contention between the Maharashtra government and the Centre

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Covaxin was granted restricted use approval in ‘clinical trial mode’ in January by the DCGI

BS Web Team
Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode

Bharat Biotech’s Covaxin on Wednesday got the nod from the subject expert committee (SEC), an independent panel set up by the Drugs Controller General of India (DCGI) to advise it, for a restricted emergency use of the Covid-19 vaccine. Covaxin was granted restricted use approval in ‘clinical trial mode’ in January by the DCGI. At that time, the phase 3 trial on 25,800 volunteers was underway. Read more
RBI takes IDBI Bank out of PCA framework after lender improves finances

Private lender IDBI Bank is out of prompt corrective action

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in